Abstract | Cancer, once thought to be caused largely by genetic alterations, is now considered to be a mixed genetic and epigenetic disease. The epigenetic landscape, which is dictated by covalent DNA and histone modifications, is profoundly altered in transformed cells. These abnormalities may arise from mutations in, or altered expression of, chromatin modifiers. Recent reports on the interplay between cellular signalling pathways and chromatin modifications add another layer of complexity to the already complex regulation of the epigenome. In this Review, we discuss these new studies and how the insights they provide can contribute to a better understanding of the molecular pathogenesis of neoplasia.
Signal transduction pathways convert environmental stimuli to changes in cell behaviour, and are thus central to the control of all biological processes. Not surprisingly, deregulation of these pathways contributes to the development of many diseases, and is particularly important in the context of cancer. Extensive studies over recent decades have identified genetic alterations in components of many signalling pathways involved in cancer, and have also led to the development of therapeutics that can successfully target some of these pathways, most notably the use of tyrosine kinase inhibitors in chronic myeloid leukaemia (CML) 1 , HER2 (also known as ERBB2) inhibitors in breast cancer 2 , BRAF inhibitors in melanoma 3 and Janus kinase 2 (JAK2) inhibitors in myeloproliferative neoplasms (MPNs) 4 . Canonical signalling pathways usually involve a cascade of protein phosphorylation events, ultimately resulting in the activation (or inactivation) of transcriptional regulators and changes in target gene expression. The kinases that comprise these pathways are largely cytoplasmic, and are therefore not generally considered to directly affect chromatin structure; yet numerous kinases, including AKT 5, 6 and JAK2 (REF. 7 ), have been shown to modify histones or proteins that control chromatin structure. Thus, although diagrams typically show these complex signalling pathways ending at transcription factors, they can also directly regulate histone proteins, and histone-or DNA-modifying enzymes.
The N-terminal tails of histones undergo extensive post-translational modifications, including phosphorylation, acetylation, methylation, ubiquitylation and sumoylation 8 . These modifications affect chromatin configuration and chromatin-DNA interactions, and subsequently regulate numerous cellular processes, including transcriptional regulation, DNA damage repair, DNA replication, genomic imprinting and X chromosome inactivation. Some histone modifications, such as histone H3-lysine 14 acetylation (H3K14Ac), H3K27Ac and H3K4 trimethylation (H3K4me3), are found at actively transcribed promoters or active enhancers, whereas others, such as H3K9me3 and H3K27me3, are considered to represent repressive marks for transcription (TABLE 1 summarizes histone modifications and their functions in transcriptional regulation). However, it is the combination of histone modifications and DNA methylation at regulatory regions in the genome, in concert with regulation by non-coding RNAs, that determines whether genes are expressed or not, and at what level. For example, many promoters in embryonic stem cells (ESCs) harbour a specific histone modification pattern that combines the activating histone mark H3K4me3 and the repressive H3K27me3 mark 9 . These 'bivalent domains' silence the developmental genes in ESCs, while keeping them poised for activation, and provide a key example of how gene expression can be determined by the combined effects of different histone marks on the same promoter.
Cancer genetic studies have focused on mutations that contribute to cell transformation, either as gain-of-function or loss-of-function genetic events. In the past few decades, many studies have demonstrated the impact of epigenetic events on cancer development, adding another dimension to our understanding of cancer. Almost 30 years ago, it was discovered that tumour cells had lower levels of genome-wide CpG island methylation Myeloproliferative neoplasms (MPNs) . A group of diseases that affect normal blood cell production in the bone marrow, which manifests as an overproduction of one or more blood cell types (red cells, white cells or platelets).
Genomic imprinting
An epigenetic phenomenon that results in a mono-allelic, parental-specific expression pattern of a subset of genes. For example, if the paternal allele of a certain gene is imprinted, and thereby silenced, then only the maternal allele of this gene can be expressed.
CpG island
A DNA region with at least 200 base pairs, and a CG percentage of more than 50%. Methylation of the CpG sites within the gene promoter can lead to gene silencing.
Transposable elements (TEs) . Small pieces of DNA that can move within the genome. TEs can modify DNA by causing mutations, inducing or repressing nearby genes, or altering levels of protein synthesis.
than their normal counterparts 10 . This global DNA hypomethy lation is thought to contribute to genomic instability, due in part to the activation of transposable elements and loss of genomic imprinting. DNA hypermethylation is also a common feature of cancer, sometimes at the promoter regions of tumour suppressor genes, leading to loss of expression of key gatekeeper genes, such as cyclin-dependent kinase inhibitor 2A (CDKN2A) and BRCA1 (REFS 11, 12) . Cancer-associated perturbations in histone modifications often occur at individual gene promoters or enhancers in a given cancer, resulting in the improper activation or repression of genes that could contribute to cancer development. However, some common events, such as the global loss of both H4K16Ac and H4K20me3, are observed in many types of human cancer 13 . In contrast to the irreversible character of genetic events, epigenetic alterations are potentially reversible. In fact, some epigenetic drugs, most notably some histone deacetylase (HDAC) and DNA methyltransferase (DNMT) inhibitors, have been approved by the US Food and Drug Administration (FDA) for the treatment of haematological malignancies 14 . Because of the complex regulation of the human epigenome, the cause of aberrant epigenetic modifications remains difficult to determine for most cancers. Nevertheless, the interplay between upstream signalling pathways and chromatin modifications represents an important molecular mechanism that leads to specific alterations in the cancer epigenome. This Review summarizes recent findings into how such crosstalk can contribute to the development of cancer.
Regulation of histone phosphorylation
Histone phosphorylation is involved in various cellular processes. Phosphorylation of H3S10 and H3S28 is associated with two seemingly paradoxical functions -transcriptional activation and chromosome condensation 15, 16 . Whereas phosphorylation of H3S10 and H3S28 by mitotic kinases such as Aurora kinase B is required for the initiation of chromosome condensation and the onset of mitosis 16 , phosphory lation at these sites by signal transduction kinases, such as ribosomal S6 kinase 2 (RSK2), mitogen-and stress-activated kinase 1 (MSK1) and MSK2, promotes the transcriptional activation of immediate-early genes, such as FOS, JUN and MYC 17, 18 . Mitotic histone H3 phosphorylation is a highly coordinated spatiotemporal event, which starts at pericentromeric heterochromatin regions at the onset of mitosis, reaches maximal abundance during metaphase and then decreases rapidly upon the transition to anaphase. Unlike the global H3 phosphorylation seen during mitosis, interphase H3 phosphorylation occurs rapidly in response to extracellular stimuli, but targets only a small fraction of nucleosomes, thus affecting only the local chromatin structure 19 . Other signalling kinases, including IκB kinase-α (IKKα) 20 , JUN N-terminal kinase (JNK) 21 and PIM1 (REF. 22 ), have also been reported to phosphorylate H3 at either S10 or S28 and control gene transcription. IKKα, a crucial regulator of nuclear factor-κB (NF-κB) signalling by controlling the stability of IκB protein (the inhibitor of NF-κB) in the cytoplasm, has been shown to shuttle into the nucleus and phosphorylate H3S10 at NF-κB-responsive promoters, thus directly affecting the cytokine-induced expression of NF-κB-regulated genes 20 . Whereas JNK-mediated H3S10 phosphorylation contributes to the differentiation of stem cells into neurons 21 , PIM1 forms a complex with MYC on MYC-responsive genes, where it phosphorylates H3S10 and facilitates MYC-induced gene expression and cellular transformation 22 . In addition to cell cycle progression and control of gene transcription, H3S10 phosphorylation by protein kinase Cδ (PKCδ) has been shown to have a role in apoptosis-induced chromatin condensation 23 . The mechanisms by which phosphorylation at these two serine residues in histone H3 affects gene expression and mitosis are still unclear. Phosphorylation of H3S10 and H3S28 has been shown to recruit the scaffolding proteins 14-3-3ε and 14-3-3ζ to the promoters of immediate-early genes, enabling the transcription initiation machinery to assemble there; the recruitment of 14-3-3 proteins is greatly enhanced when H3K14 (on the same histone H3 'tail') is simultaneously acetylated 24, 25 . As both H3S10 and H3S28 reside within an ' ARKS' sequence motif, researchers have speculated that dynamic serine phosphorylation might affect the readout of the more stable methyl marks on the adjacent lysine residues. Indeed, H3S10 phosphorylation has been shown to displace heterochromatin protein 1γ (HP1γ) from the adjacent methylated H3K9 residue, impairing its ability to propagate heterochromatin during both transcriptional activation and mitosis 26, 27 . In contrast, phosphorylation of H3S28 not only prevents the recruitment of Polycomb-repressive complexes and methylation of H3K27, but also induces a switch from methylation to acetylation at this lysine residue 28 .
We are beginning to learn how aberrant histone phosphorylation contributes to cellular transformation. For example, mutating H3S10 or H3S28 to alanine blocks the epidermal growth factor (EGF)-induced transformation of mouse epidermal cells in culture 29 , probably owing to reduced transactivation of EGF target genes, including Fos and Jun. Similarly, inhibiting MSK1 activity reduces the activation of immediate-early genes in response to oncogenic RAS-MAPK signalling, impairing tumour cell growth in soft agar colony assays 30 . Both of these observations support the importance of phosphorylation of H3S10 and H3S28 in tumorigenesis. However, neither study examined the changes in chromatin condensation that occur during mitosis when phosphorylation of H3S10 and H3S28 is inhibited.
Another example of crosstalk between histone phosphorylation and lysine methylation was reported in two studies by Metzger and colleagues 31, 32 . They showed that histone H3 is phosphorylated at T6 by PKCβ1 and at T11 by protein-kinase C-related kinase 1 (PRK1; also known as PKN1), two phospholipid-dependent kinases that are involved in cell proliferation and migration and are overexpressed in several human cancers 33 . These phosphorylation events can be androgen driven and facilitate the transactivation of androgen receptor (AR) target genes in prostate cancer cell lines. Interestingly, the ability of lysine demethylases, such as lysine-specific histone demethylase 1 (LSD1, also known as KDM1A) and Jumonji domain-containing protein 2C (JMJD2C; also known as KDM4C), to remove the methyl marks from H3K4 and H3K9 is affected by H3T6 and H3T11 phosphorylation 31, 32 . H3T6 phosphorylation blocks the demethylation of H3K4me1 and H3K4me2 by LSD1, whereas phosphorylation of H3T11 accelerates the demethylation of H3K9me3 by JMJD2C. Given the positive role of H3K4 methylation and the inhibitory effect of H3K9 methylation on gene expression, these changes to methylation would be expected to promote transcription and enhance the strength of AR-dependent gene expression. In fact, high H3T6 and H3T11 phosphorylation levels correlate with high Gleason scores (and worse prognosis) for patients with prostate cancer. In addition, inhibition of PRK1 and PKCβ1 greatly impairs the in vitro growth of prostate cancer cells, which supports at least one role of histone H3 threonine phosphorylation in promoting AR-dependent transformation 31, 32 . In addition to serine and threonine phosphorylation, histone H3 is also phosphorylated at tyrosine residues by JAK2 (REF. 34 ). JAK2 signalling has an important role in normal haematopoiesis, as it is downstream of several cytokine receptors. These pathways can be hijacked in cancer through mutations in cytokine receptor genes or in the tyrosine kinase genes themselves. For example, JAK2-V617F, a constitutively activated form of JAK2, is found in more than half of all patients with MPNs 35 . Dawson and colleagues 34 found that a substantial proportion of the cellular JAK2 protein is in the nuclei of haematopoietic cells, where it phosphorylates histone H3Y41 (FIG. 1) . Phosphorylation of H3Y41 excludes HP1 from chromatin, an event linked to the transcriptional activation of at least one JAK2-target gene, LIM domain In addition to activating its downstream transcription factors such as signal transducers and activators of transcription (STATs) the receptor-associated Janus kinase 2 (JAK2) can also affect chromatin structure via direct and indirect mechanisms. In response to extracellular stimuli, both wild type and JAK2-V617F (shown as JAK2VF) can shuttle into the nucleus and phosphorylate histone H3 at Y41. This leads to exclusion of heterochromatin protein 1 (HP1) from chromatin and activation of gene transcription at JAK2 target genes such as LIM domain only 2 (LMO2). In contrast, oncogenic JAK2-V617F, but not wild-type JAK2, can phosphorylate the arginine methyltransferase PRMT5, resulting in the dissociation of the PRMT5-methylosome protein 50 (MEP50) complex, the downregulation of PRMT5 methyltransferase activity and a decrease in symmetrical dimethylation of histones H2A and H4 at R3. Me, methyl; P, phosphate. only 2 (LMO2), a gene that is essential for normal haematopoietic development and that has been implicated in leukaemogenesis 36, 37 . Direct signalling of JAK2-V617F to chromatin was also shown to mediate ESC self-renewal via regulation of NANOG expression 38 . Using genomewide chromatin immunoprecipitation-sequencing (ChIP-seq) technology, the same group identified many more genes that are regulated through phosphorylation of H3Y41 (REF. 39 ). Furthermore, the detection of H3Y41 phosphorylation in JAK2-deficient gamma-2A cells indicates that tyrosine kinases other than JAK2 are also capable of phosphorylating H3Y41 (REF. 34 ).
Even though histone H3 seems to be the major target of upstream signalling kinases, other histones such as H2B can also be phosphorylated at multiple serine and threonine residues, providing additional mechanisms that can regulate cell behaviour. For example, AMP-activated protein kinase (AMPK), a crucial regulator of cell metabolism, controls stress-elevated gene transcription via phosphorylation of H2BS36 in both the promoters and the transcribed regions of these genes 40 .
In contrast, phosphorylation of H2BS14 by mammalian STE20-like protein kinase 1 (MST1; also known as STK4) is associated with apoptotic chromatin condensation 41 .
Together, these recent studies show that histone phosphorylation is a dynamic nuclear event involved in transcriptional regulation, chromatin condensation, apoptosis and DNA replication. In addition, histone phosphorylation can regulate DNA repair (which we describe further below). 42 provides more detailed information on the role of kinases in the regulation of histone modifications.
Regulation of histone-modifying enzymes
Histone-modifying enzymes can be categorized into 'writers' and 'erasers' that add or remove covalent post-translational modifications to histones, respectively
. Many of these writer or eraser enzymes are either mutated or aberrantly expressed in cancer, where they may play a pivotal and targetable role.
Regulation of Polycomb group proteins: EZH2 and BMI1. Polycomb group (PcG) proteins were initially identified as key factors that regulate developmental pathways 43 , maintaining the repression of homeobox gene expression and antagonizing the activities of trithorax proteins during embryogenesis. PcG proteins AMPK, AMP-activated protein kinase; ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related; CHK1, checkpoint kinase 1; CK2, casein kinase 2; DAG, diacylglycerol; DNA-PK, DNA-dependent protein kinase; IKKα, IκB kinase-α; JAK2, Janus kinase 2; JNK, JUN N-terminal kinase; LKB1, liver kinase B1; MSK, mitogenand stress-activated kinase; MST1, mammalian STE20-like kinase 1; NF-κB, nuclear factor-κB; PKC, protein kinase C; PRK1, protein-kinase C-related kinase 1; RSK, ribosomal S6 kinase; WSTF, Williams syndrome transcription factor.
Myelodysplastic syndrome (MDS).
A haematological medical condition, also known as myelodysplasia, that is characterized by ineffective production of myeloid lineage blood cells and a disorder of the haematopoietic stem cells in the bone marrow. Patients with MDS are at high risk of progression to leukaemia.
were later found to be crucial for controlling gene expression, and essential for many cellular processes, including cell-fate decisions during embryogenesis 44 , maintenance of ESC pluripotency 45 and preservation of adult stem cell self-renewal 46 . These proteins are structurally and functionally diverse and are found in two major multimeric protein complexes, PcG repressive complex 1 (PRC1) and PRC2
.
Misregulation of these PRCs has now been implicated in the initiation and development of several cancers. The PRC2 component enhancer of zeste homologue 2 (EZH2) is frequently overexpressed in many advanced-stage or metastatic solid tumours, including prostate and breast cancer 47, 48 . Both gain-of-function and loss-of-function mutations in EZH2 are found in human cancer. The methyltransferase activity of EZH2 is altered by mutations at Y641 in lymphomas 49, 50 ; these mutations enhance its catalytic efficency for the dimethylation to trimethylation reaction of H3K27 but ablate its ability to catalyse the monomethylation of the unmethylated H3K27 residue 51 . In contrast, loss-of-function mutations are found in patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) 52 . Given the crucial role of EZH2 in stem cell maintenance and tumorigenesis, these mutations are likely to have a pathogenic role.
Bmi1 (also known as Pcgf4), which encodes a central component of many PRC1 complexes, was first identified as a proto-oncogene capable of inducing lymphomas in mice in cooperation with Myc 53, 54 . BMI1 has an important role in haematopoietic and neural stem cell self-renewal 55, 56 , and upregulation of BMI1 has been detected in AML and CML 57 , as well as in many solid tumours, including squamous cell carcinomas 58 , neuroblastoma 59 and bladder cancer 60 . The oncogenic potential of BMI1 has been associated with its ability to repress the CDKN2A locus, blocking the expression of the two proteins encoded by this locus, the cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitor p16 INK4A , and the p53 activator p14 ARF (p19 ARF in mouse) 61 .
There is growing evidence that signalling pathways can regulate the functions of EZH2 and BMI1 (FIG. 2) . Starting from the observation that cells with higher levels of activated AKT have lower levels of H3K27me, Cha et al. 5 demonstrated that AKT phosphorylates EZH2 on S21, repressing its methyltransferase activity towards H3K27 by impairing its recruitment to chromatin. Inhibition of AKT activity increases global H3K27me3, and decreases the expression of the EZH2 target gene homeobox A9 (HOXA9). EZH2 phosphorylation changes its substrate specificity, directing its methyltransferase activity towards non-histone substrates. The authors further showed that a phosphomimetic form of EZH2 enhanced cell growth in vitro and tumour development in vivo, indicating the important role of this phosphorylation event in its transforming ability. The EZH2-containing PRC2 complex is found in the cytoplasm, where it can function in actin polymerization and signal transduction 62 ; it is still not known which non-histone substrates of EZH2 are important for its transforming ability.
Multiple signalling pathways have been shown to phosphorylate and regulate BMI1 activity. The association of BMI1 with chromatin is cell cycle regulated: BMI1 is hyperphosphorylated during G2/M, when it disassociates from chromatin, but it is dephosphory lated and retained on chromatin during G1/S 63 . Although the enzyme responsible for BMI1 phosphorylation was not identified in this study, it is likely to be a cell cycleregulated kinase. BMI1 is also a downstream target of the RAS-MAPK pathway 64 . MAPKAP kinase 3 (3pK; also known as MAPKAPK3), a convergence point of both the RAS-ERK and the RAS-p38 signalling pathways, phosphorylates BMI1, resulting in its disassociation from chromatin, derepression of the CDKN2A locus and upregulation of p14 ARF expression. We and two other groups 6, 65, 66 , have reported that BMI1 is phosphorylated by PI3K-AKT signalling, although the consequences of phosphory lation on BMI1 function varied between these reports. Kim et al. 65 showed that AKT-mediated phosphorylation of BMI1 prevents its degradation, resulting in BMI1 accumulation in the nucleus of neural stem cells (NSCs), leading to an increase in histone H2A ubiquitylation and a decrease in p21 expression. BMI1 has been reported by several groups to play a crucial part in DNA damage repair 67, 68 . Using prostate cancer as a model, the van Lohuizen group 66 reported that phosphorylation of BMI1 by AKT is required for DNA damage-induced ubiquitylation (Ub) of H2A and γH2AX at sites of double-strand breaks and for efficient DNA repair. However, neither the global level of H2A-Ub nor the expression of BMI1 target genes is altered by this phosphorylation. We found that AKT phosphorylates BMI1 on S316 (REF. 6 ), an AKTconsensus site, triggering the disassociation of the PRC1 complex from chromatin, resulting in decreased global H2A mono-ubiquitylation, and increased expression of p16 INK4A and p19 ARF in mouse embryonic fibroblasts (MEFs). BMI1 has an important role in the selfrenewal of haematopoietic stem cells (HSCs), where • Epigenetic writers are enzymes that lay down epigenetic marks on histone tails • Epigenetic erasers are enzymes that revert histone modifications • Epigenetic readers are proteins that recognize epigenetic marks Most histone modification patterns are established by histone acetyltransferases (HATs) or histone methyltransferases (HMTs), which can be further classified as lysine methyltransferases and arginine methyltransferases according to their target residue. Histone tails can also be modified by kinases, ubiquitin ligases and E2 SUMO-conjugating enzymes. These enzymes are usually specific to particular amino acid motifs and target both core histones (such as H3) and histone variants (such as H3.3) 161 . Epigenetic marks are generally dynamic and can be modified or removed by various enzymes. Histone lysine acetylation and methylation are removed by histone deacetylases (HDACs) and histone demethylases, respectively. Histone phosphatases can target phosphorylated serine, threonine and tyrosine in histone tails. The removal of histone mono-ubiquitylation is carried out by deubiquitylating enzymes 161 . The key function of histone modifications is to signal to recruit effectors and epigenetic readers to the local chromatin; these proteins ultimately determine the transcriptional outcome of certain epigenetic modifications 162 .
Oesophageal squamous cell carcinoma
A type of cancer that begins in the flat squamous cells lining the oesophagus. Smoking and heavy alcohol use increase the risk of this disease.
Lung sarcomatoid carcinoma
A rare and heterogeneous group of aggressive lung carcinomas, with histological features that resemble those of a sarcoma.
Desmoplastic medulloblastoma
A histological subtype of medulloblastoma, the most common malignant brain tumour in children, that is characterized by nodular structures that contain reticulin-free zones surrounded by densely packed highly proliferative cells.
AKT signalling is inactive 55, [69] [70] [71] . We found that AKTmediated phosphorylation of BMI1 inhibits its ability to promote HSC self-renewal. This observation may explain why progenitor cells that have active AKT signalling have limited self-renewal ability and why constitutively activated AKT leads to HSC depletion 72, 73 . Together, these studies indicate that BMI1 phosphorylation occurs following oxidative stress, DNA damage and HSC differentiation, suggesting that BMI1 is a convergence point for multiple signalling pathways. The different functional outcomes of BMI1 phosphorylation may reflect both site-specific and cell context-specific variations. For example, AKT is capable of phosphorylating BMI1 at distinct serine residue(s) in different cell types under different conditions, resulting in enhanced or diminished BMI1 function 6, 65, 66 . Furthermore, given the importance of BMI1 in cellular senescence 74 , its inhibition by oncogenic pathways such as RAS-MAPK and PI3K-AKT could be a potential mechanism underlying oncogene-driven senescence.
Regulation of histone lysine demethylases. Two evolutionarily conserved families of histone lysine de methylases have been identified: the LSD family and the Jumonji (JMJ) family. LSDs, which include LSD1 and LSD2 (also known as KDM1B), catalyse the demethylation of mono-and dimethylated H3K4 and H3K9 (REF. 75 ). The 30 members of the JMJC demethylase family have activity against methylated H3K4, H3K9, H3K27, H3K36 and H4K20 (REF. 75 ).
Recurrent genetic alterations, including mutations, gene amplifications and deletions of lysine demethylases, have been noted in cancer. Mutations in KDM6A (also known as UTX), which encodes an H3K27 demethylase, are seen in various solid and haematological cancers 76 , whereas KDM4A (also known as JMJD2), which encodes an H3K9 demethylase, is frequently amplified and overexpressed in oesophageal squamous cell carcinoma, lung sarcomatoid carcinoma and desmoplastic medulloblastoma 77 . Similarly, LSD1 is overexpressed in multiple cancer types, and high LSD1 expression correlates with poor clinical outcomes in these cancers [78] [79] [80] [81] .
In addition to being affected by somatic mutations, the activity of these erasers is also regulated by upstream oncogenic signalling pathways, which provide another way of altering their function. For instance, the expression of JMJD3 (also known as KDM6B) is induced by oncogenic RAS-RAF signalling, leading to demethylation of H3K27me3 at the CDKN2A locus, and increased p16 INK4A expression 82 (FIG. 2) . These results suggest an important role for JMJD3 in triggering oncogene-or stress-induced senescence, two fail-safe mechanisms that help to prevent malignant transformation. Indeed, JMJD3 expression is significantly reduced in lung and liver cancer, and in haematological malignancies 82 . Furthermore, the TP53 (which encodes p53) and JMJD3 genes are located in close proximity at 17p, a region frequently lost in several human cancers 83 . This suggests that JMJD3 may have a tumour suppressor role, similar to the known tumour suppressor role of p53.
Regulation of histone arginine methylation. In addition to lysine methylation, histones are methylated on arginine residues, a reaction that is catalysed by the protein arginine methyltransferases (PRMTs). Nine PRMTs have been identified in mammalian cells, and classified into two major groups based on their ability to catalyse either the asymmetrical (type I enzymes) or the symmetrical (type II enzymes) dimethylation of arginine residues in histone and non-histone proteins 84, 85 . PRMT7 seems to exhibit type III enzymatic activity -namely the ability to catalyse the formation of monomethylated but not dimethylated arginine 86 . Arginine methylation of proteins has been implicated in various cellular processes, including transcriptional regulation, signal transduction, DNA repair and RNA processing 87 . PRMT5 is the major type II arginine methyltransferase in mammalian cells, which catalyses symmetrical dimethylation of histones H2A, H3 and H4 as well as of non-histone proteins, including p53, methyl-CpG-binding domain protein 2 (MBD2) and the Sm ribonucleoproteins [91] [92] [93] . The role of PRMT5 in lymphomagenesis, leukaemogenesis and in the genesis of solid tumours is rapidly being unravelled. PRMT5 is overexpressed in leukaemia and lymphoma, as well as in many types of solid tumour, suggesting a potential oncogenic role 94 . The Sif group 95 first reported that the level of PRMT5 was elevated in primary lymphoma samples and cell lines, where it represses the expression of the retinoblastoma tumour suppressor proteins: RB1, RBL1 and RBL2. PRMT5 upregulation is induced by the ectopic expression of several oncogenes, including NOTCH1, the mixed lineage leukaemia (MLL) fusion gene MLL-AF9 (also known as KMT2A-MLLT3) and MYC 96 . In addition to repressing the expression of tumour suppressor genes, upregulation of PRMT5 also maintains proper pre-mRNA splicing in lymphoma cells 97 . Treating mantle cell lymphoma cells with PRMT5-specific inhibitors shows promising in vitro and in vivo antitumour activity 98 . PRMT5 was originally identified in a yeast twohybrid assay as JAK binding protein 1 (REF. 99 ). We therefore investigated the interaction between PRMT5
Box 2 | Components of PRC1 and PRC2 complexes
The core Polycomb repressive complex 2 (PRC2), which is conserved from Drosophila melanogaster to mammals, comprises four components: enhancer of zeste homologue 1 (EZH1) or EZH2, suppressor of zeste 12 protein homologue (SUZ12), embryonic ectoderm development (EED) and RBAP46 (also known as RBBP7) or RBAP48 (also known as RBBP4). EZH1 and EZH2 are histone methyltransferases that catalyse H3K27 methylation 163 . The PRC1 complex is more variable than PRC2 and is formed by four different orthologues: chromobox protein homologue (CBX), Polycomb group RING finger protein (PCGF), human polyhomeotic homologue (HPH) and an E3 ubiquitin ligase protein (RING) that catalyses the mono-ubiquitylation of histone H2A on lysine 119 (H2AK119ub) 164 . H3K27 trimethylation and H2AK119 mono-ubiquitylation are major repressive marks that inhibit transcription and help to regulate the expression of development-related transcription factors, such as those encoded by clusters of HOX genes, as well as other genes that control cell proliferation, such as cyclin D2 (CCND2) 165 . 
S-adenosylmethionine
A universal methyl group donor that is critical for the synthesis of hormones, phospholipids and macromolecules in the cell. An important cofactor for methyltransferase proteins.
Rubinstein-Taybi syndrome (RTS).
A condition characterized by short stature, moderate to severe intellectual disability, distinctive facial features and broad thumbs and first toes. Mutations in the genes CREBBP and EP300 (encoding CREB binding protein (CBP) and p300, respectively) are seen in some people with this condition.
and JAK2 given the high frequency of the JAK2-V617F mutation in patients with MPNs, which suggested that this mutation might generate a specific gain-of-function, rather than simply constitutively activating JAK2 kinase activity 7 . Indeed, we found that JAK2-V617F interacts more strongly with PRMT5 than wild-type JAK2, and that it gained the ability to phosphorylate PRMT5 and downregulate its histone methyltransferase activity by disrupting the interaction between PRMT5 and its cofactor methylosome protein 50 (MEP50). Treating JAK2-V617F-harbouring cells with JAK2 inhibitors rapidly upregulated global H2AR3 and H4R3 symmetrical dimethylation, providing an example of how an oncogenic tyrosine kinase can affect a specific chromatin modification by altering the activity of a histone-modifying enzyme. However, JAK2 inhibitors did not affect the symmetrical methylation of all proteins examined, suggesting differential sensitivity of various PRMT5 substrates in the cell. This observation may reflect the intracellular location at which the phosphorylation occurs (for example, in the cytoplasm or nucleus), or the differential effects of phosphorylation on the various PRMT5 complexes found in the cell. We have also recently shown that PRMT5 is essential for the proliferation and survival of adult haematopoietic stem and progenitor cells, in part owing to its role in regulating multiple cytokine signalling pathways 100 .
Whereas we showed that phospho-PRMT5 (catalysed by JAK2-V617F) no longer binds to MEP50, Aggarwal et al. 101 showed that the mutant cyclin D1-T286A-CDK4 complex, which is found in some non-Hodgkin lymphomas, phosphorylates MEP50 and increases PRMT5 methyltransferase activity towards histones H4R3 and H3R8. This leads to decreased expression of the ubiquitin ligases cullin 4A (CUL4A) and CUL4B, and stabilization of the DNA replication factor CDT1, which triggers DNA re-replication and enhances genomic instability. In a recent report by the same group 96 , PRMT5 activation via MEP50 phosphorylation was shown to impair p53 signalling, further promoting cyclin D1-T286A-mediated transformation.
The activity of other PRMTs is also controlled by phosphorylation. For instance, PRMT4, originally identified as a co-activator for the nuclear hormone receptors 102 is phosphorylated at S217 and S228, probably by a mitotic kinase; this disrupts its interaction with the methyl donor S-adenosylmethionine (SAM), and represses its methyltransferase activity 103, 104 . These studies suggest a potential role of PRMT4 regulation in cell cycle progression; however, neither study identified the kinase(s) involved.
Regulation of histone acetylation. Two highly homologous histone lysine (K) acetyltransferases (KATs, formerly called HATs), p300 and CREB binding protein (CBP; also known as CREBBP), are recruited to chromatin by sequence-specific transcription factors, leading to histone acetylation, localized chromatin remodelling and ultimately, the activation of specific gene expression programmes 105 . Both enzymes can function as tumour suppressors. For example, patients with Rubinstein-Taybi syndrome (RTS), which is caused by germline mutations that disrupt CBP or p300 function, have an increased predisposition to develop tumours of neural and developmental origin 106 . Somatic loss-of-function mutations are also seen in the genes encoding these two enzymes in lymphomas and in solid tumours, including colorectal cancer and gastric cancer 107 . Chromosome translocations that fuse CREBBP (the gene encoding CBP) with the lysine acetyltransferase 6A (KAT6A; also known as MOZ or MYST3) are found in t(8;16) AML 108 ; these translocations generate haploinsufficiency for CBP, in addition to the gain-of-function that is intrinsic to the fusion proteins they generate.
Both p300 and CBP are phosphorylated at multiple serine, threonine and tyrosine residues by various signal transduction pathways (FIG. 3) . The functional consequences of these phosphorylation events are diverse, affecting the enzymatic activity, protein stability and protein-protein interactions of these two enzymes. p300 was first shown to be phosphorylated by cyclin-CDK2, and this phosphorylation is blocked by the adenovirus E1A proteins 109 . CDK1 phosphorylates p300 at S1038 and S2039 during mitosis, leading to p300 degradation, which contributes to cell cycle progression by facilitating chromatin condensation in mitotic lung cancer cells 110 . Whereas phosphorylation These complexes are subject to intensive regulation from upstream signalling pathways, including the PI3K-AKT and RAS-MAPK pathways. Activated AKT phosphorylates both EZH2 and BMI1, two crucial components of the PRC2 and PRC1 complexes, respectively. Phosphorylation of EZH2 inhibits H3K27 methylation by the PRC2 complex, and phosphorylation of BMI1 decreases the association of the PRC1 complex with chromatin, leading to decreased H2AK119Ub. BMI1 can also be phosphorylated by activated MAPKAP kinase 3 (3pK), leading to the impaired recruitment of PRC1 to chromatin. Furthermore, MAPK signalling upregulates the expression of the histone demethylase JMJD3, which removes the H3K27 methyl mark that is added by the PRC2 complex. These changes then contribute to upregulation of the cyclin-dependent kinase 2A (CDKN2A) products p16
INK4A
, p14 ARF (human) and p19 ARF (mouse), leading to oncogene-induced cell senescence. Me, methyl; P, phosphate; Ub, ubiquitin. of p300 by AKT (at S1834) enhances its HAT activity and its recruitment to gene promoters 111 , its phosphorylation by PKCα, PKCβII and PKCδ (at S89) impairs its ability to activate transcription 112, 113 . AMPK also phosphorylates p300 (at S89), reducing its affinity for nuclear receptors (NRs), which leads to decreased transcription of NR target genes. Nevertheless, S89 phosphorylation does not affect the interactions of p300 with non-NR transcription factors, such as p53 and GATA binding protein 4 (GATA4) 114 . Ataxia telangiectasia mutated (ATM) phosphorylates p300 at S106, leading to protein stabilization 115 . Furthermore, p300 phosphorylation by PKA or p38 impairs protein stability, triggering protein degradation by the ubiquitin-proteasome pathway 116, 117 . Phosphorylation of CBP at its C terminus, by ERK1 and the cyclin E-CDK2 complex (which functions at the G1/S boundary), increases its enzymatic activity towards histones 118, 119 , whereas calcium/calmodulindependent protein kinase IV (CAMKIV) phosphorylates CBP at its N terminus (S302) and stimulates its acetyltransferase activity in cultured neurons 120 . Phosphorylation of CBP (at S1382 and S1386) by IKKα enhances its HAT activity, and switches its binding preference from p53 to NF-κB 121 . This enhances transcription of NF-κB target genes and decreases transcription of p53 target genes, thereby promoting cell proliferation, and possibly tumour progression. A positive correlation between IKKα activity and CBP phosphorylation was found in various cancer cell lines, indicating that CBP phosphorylation may promote NF-κB-mediated tumorigenesis 121 . Given the diverse functions of p300 and CBP, it seems that the availability of these proteins can be a rate-limiting factor for many biological processes, including transcriptional regulation and cell cycle progression. Thus the tight regulation of the activity of p300 and CBP by various signal transduction pathways provides a crucial layer of control for these cellular events 122 . The aberrant expression of, and mutations in, genes encoding HDACs have also been linked to tumorigenesis, and the more specific targeting of these enzymes is a promising therapeutic approach for some types of cancer. HDAC function is regulated by phosphorylation: the class II HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) are phosphorylated by multiple signalling kinases at their N-terminal regulatory regions, and phosphorylation-dependent interaction with 14-3-3 proteins triggers the nuclear export of HDACs, leading to derepression of their target genes 123 . Casein kinase 2 (CK2) seems to be the major signalling kinase that phosphorylates the class I HDACs, HDAC1 and HDAC2, under hypoxic conditions 124 . Phosphorylation-dependent activation of these HDACs is involved in the downregulation of von Hippel-Lindau protein (VHL protein) and subsequent stabilization of hypoxia inducible factor 1α (HIF1α). Therefore, targeting CK2 in hypoxic tumours may be a potential therapeutic approach.
DNA damage and chromatin modification
The DNA damage response (DDR) represents a major signalling pathway that maintains the integrity and accuracy of genetic information, and suppresses mutagenic events that could be tumorigenic 125 . The DDR is intimately related to changes in chromatin structure, via phosphorylation of histones and histone modifiers (FIG. 4) . Phosphorylation of H2AX at S139 (which is generally referred to as γH2AX) by the PI3K-like family of kinases (which includes ATM, ataxia telangiectasia and Rad3-related (ATR) and the DNA-dependent protein kinase catalytic subunit (DNA-PKcs)) seems to be the first histone modification following DNA damage 126 . γH2AX recruits not only molecules that sense or signal the presence of DNA breaks, but also histone modifiers, including ubiquitin ligases and histone methyltransferases, to further modify the local chromatin structure and activate cellular processes that lead to repair of the DNA damage. Other histone phosphorylation events induced by DNA damage include H2B phosphorylation (at S14) by MST1, leading to chromatin condensation and apoptosis 41 , and H4 phosphorylation (at S1) by CK2, which facilitates DNA repair and blocks local H4 acetylation by the NuA4 histone acetyltransferase complex 127, 128 . The decision of cells to undergo cell cycle arrest and repair the damaged DNA or to undergo cell death after DNA damage occurs reflects the integration of several upstream signals. For instance, H2AX is constitutively phosphorylated at Y142 by the tyrosine kinase Williams syndrome transcription factor (WSTF; also known as BAZ1B) 129 . Upon DNA damage, Figure 3 | The extensive regulation of CBP and p300 histone acetyltransferase activity by signalling kinases. Both CREB binding protein (CBP) and p300 are phosphoproteins, and they are regulated by several signalling pathways. These kinase-dependent and site-specific phosphorylation events variably affect the histone acetyltransferase (HAT) activity of these histone lysine acetyltransferases (KATs) via changes in protein stability and protein-protein interactions. AMPK, AMP-activated protein kinase; ATM, ataxia telangiectasia mutated; Bro, bromodomain; CAMKIV, calcium/calmodulin-dependent protein kinase IV; CDK, cyclin-dependent kinase; IKKα, IκB kinase-α; KIX, kinase-inducible domain interacting; NF-κB, nuclear factor-κB; NR, nuclear receptor; PKA, protein kinase A; PKC, protein kinase C. www.nature.com/nrc © 2 0 1 6 M a c m i l l a n P u b l i s h e r s L i m i t e d . A l l r i g h t s r e s e r v e d .
Me Ac
Nature Reviews | Cancer Ataxia telangiectasia (A-T). An inherited disease that affects several body systems, including the immune system and the central nervous system; patients with A-T have a high rate of cancer.
Bloom syndrome
An inherited disorder that causes growth defects, chromosomal instability and a predisposition to cancer. This disorder is induced by mutations in BLM, which encodes a RecQ helicase, a family of enzymes that maintain DNA integrity.
this tyrosine residue can either remain phosphorylated or be dephosphorylated (by the phosphatases eyes absent homologue 1 (EYA1) and EYA3) 130 . Intriguingly, the phosphorylation status of Y142 affects the function of the nearby S139 residue, a site phosphorylated in response to DNA damage. Dephosphorylation of Y142 enables the recruitment of DNA repair complexes by phosphorylated S139, leading to DNA repair and cell survival. In contrast, phosphorylated Y142 facilitates the recruitment of pro-apoptotic factors by phosphory lated S139, leading to cell death. Thus, phosphorylation at Y142 on H2AX acts as a key switch that regulates cellular decisions following DNA damage 130 . Phosphorylation at H3T11 is another mechanism that regulates such decisions 131 . This residue is phosphory lated by checkpoint kinase 1 (CHK1) during the cell cycle, and its phosphorylation generally decreases upon DNA damage owing to the disassociation of CHK1 from chromatin. This reduces the recruitment of the KAT GCN5 (also known as KAT2A) to the promoters of cell cycle regulatory genes, such as CDK1 and cyclin B1 (CCNB1), leading to less H3K9 acetylation at these promoters and decreased gene expression. Thus, the reduced phosphorylation of H3T11 contributes to transcriptional repression and cell cycle arrest following DNA damage.
In addition to histones, histone-modifying enzymes can also be post-translationally regulated by the DDR. For example, the DDR triggers phosphorylation of the H3K4 methyltransferase MLL on S516 by ATR, disrupting its interaction with S-phase kinase-associated protein 2 (SKP2) E3 ubiquitin ligase and preventing its degradation 132 . At S-phase, the accumulated MLL methylates H3K4 on the β-globin origin of DNA replication, which can impair the loading of cell division control protein 45 (CDC45) onto chromatin, delaying the initiation of DNA replication. Interestingly, oncogenic MLL fusions (such as MLL-AF4 and MLL-AF9), function as dominant negative mutants to block this S-phase checkpoint, representing a potential mechanism of MLL fusion-mediated transformation 132 . The various histone modifications induced by DDR are crucial for DNA damage sensing and signalling, repair of the lesion and cell cycle arrest and release of the cell back into the cycle 133 . Mutations in genes that encode DDR proteins can result in several genomic instability syndromes, including Fanconi anaemia, ataxia telangiectasia and Bloom syndrome, that lead to an increased risk of leukaemia and other cancers, demonstrating an important role of DDR in the pathogenesis of cancer 134 . Moreover, induction of DNA damage is one important strategy for cancer treatment; therefore, drugs that target the enzymes responsible for these modifications could be very promising therapeutics 135 .
Regulation of DNA methylation DNA methylation is established in mammalian cells by two types of DNMT. The de novo DNMTs, DNMT3A and DNMT3B, act on hemimethylated or unmethylated DNA, and are essential for establishing DNA methylation patterns during development. The 'maintenance DNMT' , DNMT1, acts preferentially on hemimethylated DNA, and ensures the propagation of tissue-specific methylation patterns 136 . Alterations in DNA methylation are a hallmark of cancer 11
, and aberrant regulation of DNA methylation is commonly seen in the haematopoietic malignancies, including recurrent mutations in DNMT3A and in the DNA methylcytosine hydroxylase TET2 in Figure 4 | The DNA damage response modulates chromatin modifications. DNA damage triggers various changes in chromatin modifications via direct phosphorylation and/or dephosphorylation of histones such as H2A, H2B and H3, as well as the phosphorylation of histone modifiers such as mixed lineage leukaemia 1 (MLL1), ultimately leading to cell cycle arrest and repair of DNA damage, or apoptosis-mediated cell death. Ac, acetyl; ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related; CDC45, cell division control protein 45; CHK1, checkpoint kinase 1; DNA-PK, DNA-dependent protein kinase; EYA, eyes absent homologue; Me, methyl; MST1, mammalian STE20-like kinase 1; P, phosphate.
Box 3 | DNA epigenetic modifications that can be altered in cancer
There are several different types of DNA epigenetic modification that have shown changes in cancer 166, 167 .
• Large organized chromatin lysine modifications (LOCKs), which are usually heterochromatic, are reduced or lost in cancer • Long blocks of DNA (median size 28 kb) found around LOCKs and lamin-associated domains (LADs), which usually have high levels of DNA methylation, are hypomethylated in cancer • Many tumour suppressor genes, such as cyclin-dependent kinase inhibitor 2A (CDNK2A) and BRCA1, are linked to hypermethylated CpG islands in cancer 168 • The sharp boundaries between CpG islands and shores are lost in cancers, and DNA methylation is remarkably hypervariable at shores or boundaries in these cancer cells
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Epithelial-mesenchymal transition
The process by which epithelial cells lose cell-cell junctions and baso-apical polarity and acquire plasticity, mobility, invasive capacity, stem-like characteristics and resistance to apoptosis. 
Oestrogen receptor (ER

Progesterone receptor
The intracellular receptor activated by the steroid hormone progesterone, which is often overexpressed in breast cancer.
patients with MPN, MDS and AML 137 . Recent studies have demonstrated that mutations in these genes are found in a significant fraction of normal elderly individuals with age-associated clonal haematopoiesis 138, 139 ; these data and data on variant allele frequency suggest that mutations in these enzymes are likely primary events that lead to transformation. As many signalling pathways have been implicated in directly controlling DNA methylation 140, 141 , the co-occurrence of oncogenic tyrosine kinase mutations with mutations in DNMT3A (for example, FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD) and DNMT3A-R882C or DNMT3A-R822H in a subset of AMLs 137 ) could represent the synergistic triggering of aberrant DNA methylation in cancer.
Regulation of DNMT activity via phosphorylation.
Ectopic expression of DNMT1 in NIH 3T3 fibroblasts transforms these cells 142 , suggesting that it has a potential oncogenic role. Overexpression of DNMT1 has been reported in some types of cancer, including AML 143 , breast cancer 144 and colon cancer 145 ; however, many tumours have normal levels of DNMT1 expression. Several studies have reported that DNMT1 is phosphorylated on multiple sites within its N terminus (DNMT1 is phosphorylated at S154 by CDK1, CDK2 and CDK5), and this phosphorylation is important in regulating its enzymatic activity and protein stability 146 . SET domain-containing protein 7 (SETD7) methylates DNMT1 at K142, which triggers its degradation. However, this methylation is blocked by AKT, which phosphorylates DNMT1 on S143, leading to its stabilization 147 . DNMT1 is positively regulated by oncogenic RAS signalling at multiple levels. Elevated RAS signalling may induce DNMT1 expression through JUN activation, as several AP1 binding sites (which are binding motifs for JUN) are found in the 5′ upstream regulatory regions of DNMT1 (REF. 148 ). The converse is also true: forced expression of GAP (also known as RASA1), a negative regulator of RAS activity, decreases DNMT1 expression and global levels of DNA methylation, which can reverse cellular transformation 141 . In contrast, both PI3K-AKT and PKC-dependent signalling can phosphorylate DNMT1 (disrupting the DNMT1-proliferating cell nuclear antigen (PCNA)-UHRF1 replication complex), which leads to global hypomethylation and genomic instability 149 . DNMT1 can also be phosphorylated by CK1δ and CK1ε, which impairs its affinity for DNA 150 . Thus, multiple signalling pathways regulate DNMT1 in a cell type-and context-specific manner, resulting in increases or decreases in its methyltransferase activity, and ultimately, can result in alterations in DNA methylation patterns (FIG. 5) .
In addition to DNMT1, the activity of DNMT3A is also regulated by phosphorylation, as its phosphory lation by CK2 is required for the recruitment of DNMT3A to heterochromatic regions to silence repetitive elements in cells 151 .
Regulation of promoter hypermethylation of tumour suppressor genes in cancer. The constitutive activation of HRAS or KRAS has been shown to lead to promoter hypermethylation and to transcriptional silencing of numerous tumour suppressor genes, including those encoding the cell death-inducing protein FAS, the apoptosis-promoting protein PAR4, the RAS effector RASSF2 and O 6 -methylguanine-DNA methyltransferase (MGMT) 152 . Transforming growth factor-β (TGFβ) signalling is hyperactive in breast cancer cells during the epithelialmesenchymal transition (EMT), and the increased promoter DNA methylation triggered by this signalling pathway silences genes involved in cell adhesion and tight-junction formation, such as cadherin 1 (CHD1), cingulin (CGN), claudin 4 (CLDN4) and kallikrein-related peptidase 10 (KLK10 ; also known as NES1) 153 . Nuclear hormone receptor signalling also regulates DNA methylation at specific target gene promoters. For instance, the resistance of human cancer cells to the growth inhibitory effects of retinoic acid (RA) is associated with promoter hypermethylation of the retinoic acid receptor β2 (RARB2) gene 154 . Inhibition of RA signalling induces a repressed chromatin state at RARB2 and its transcriptional silencing. In contrast, loss of oestrogen receptor (ER) signalling in breast cancer cells results in epigenetic silencing of ER target genes, including the progesterone receptor (PGR), largely due to the recruitment of the PRC2 complex and HDAC1 to the promoters of these genes. This leads to the progressive accumulation of DNA methylation at these promoters; thus, reactivation of PGR expression requires both ER signalling and DNA demethylation 155 . The available evidence shows that oncogenic signalling shapes the DNA methylation pattern in cancer cells by controlling the expression levels of DNMTs, regulating the enzymatic activity or protein stability of DNMTs, directly affecting the binding of DNMTs to DNA, where they can regulate the local DNA methylation levels. Given the crosstalk between DNA methy lation and histone modifications 156 , the signalling pathways that contribute to cancer-specific DNA methylation patterns can also affect global and local histone modifications. Multiple signalling cascades, including RAS-MAPK, PI3K-AKT, protein kinase C (PKC), casein kinase 1 (CK1) and cyclin-dependent kinases (CDKs), phosphorylate DNA methyltransferase 1 (DNMT1) in a cell type-specific and context-dependent manner, resulting in increases or decreases in cellular DNA methylation. RAS signalling upregulates DNMT1 expression, consistent with its transforming activity. Me, methyl; P, phosphate; SETD7, SET domain-containing protein 7. Nature Reviews | Cancer 
Conclusions
We have summarized recent findings on the crosstalk between cellular signalling pathways and epigenetic elements, with a focus on how the epigenetic landscape in cancer cells is affected by aberrant growth control signalling. This regulation seems to be varied and complex, but it has a crucial role in the numerous biological processes that are involved in cell transformation. During normal development, appropriate temporal and spatial changes in the pattern of DNA methylation and histone modifications are essential to ensure that each cell in the body differentiates to its required cell fate. This generally unidirectional process involves the stepwise silencing of genes associated with developmental potential and the activation of tissue-specific gene programmes. Thus, alterations in epigenetic modifications can disrupt normal developmental pathways and interfere with cell differentiation, ultimately leading to cellular transformation 157 . Relatively little is known about how the abnormal cancer epigenome is established, although several potential mechanisms have been proposed. First, it has been shown that epigenetic modifier genes are expressed in a tissue-specific pattern and are differentially expressed in tumour cells compared with their normal counterparts (for example, increased EZH2 expression in aggressive breast or prostate cancer) 158 . Second, the genetic alterations that lead to loss-of-function or gain-of-function mutations in epigenetic-modifying enzymes are observed in the large subset of cancers that have an aberrant epigenetic landscape 159 . Third, non-coding RNAs have been shown to have a role in controlling the distribution of epigenetic marks 160 . Finally, as reviewed in this article, various oncogenic kinases can affect DNA and histone modifications via either direct phosphorylation of histones or phosphorylation of epigenetic-modifying enzymes.
These discoveries have several implications for the field of cancer epigenetics. They raise the possibility that the aberrant epigenomes seen in tumour cells without epigenetic mutations could be caused by oncogenic mutations that alter upstream signalling pathways. For example, the MPN-associated mutant JAK2-V617F gains the ability to inhibit PRMT5 function and decrease H2AR3 and H4R3 symmetrical methylation; thus JAK2-V617F-positive cells may have decreased levels of global symmetrical dimethylation of H2AR3 and H4R3 compared with normal cells, even though both cell types may have identical levels of PRMT5 protein.
Traditionally, oncogenic kinases were thought to affect gene expression primarily through activation or repression of downstream transcription factors. By gaining the ability to regulate histone and DNA modifications, oncogenic kinases can affect the overall and local chromatin structure and have a profound influence on gene expression and genomic stability, with the latter potentially leading to more aberrations within the cancer cell genome. It is likely that the crosstalk between genetics and epigenetics is an important mechanism that underlies the aberrant cell behaviours that result in tumorigenesis.
One key feature of epigenetic regulation is its inheritance, the passing of 'epigenetic memory' to the next generation of cells. This ensures the long-term maintenance of epigenetic patterns even after the initiating developmental and environmental cues have been removed. In contrast, most signalling transduction pathways are much more dynamic, and are fine-tuned by numerous kinases and phosphatases to ensure quick responses to exogenous stimuli. However, the modulation of chromatin marks by upstream signalling pathways enables these pathways to leave their 'fingerprints' on gene expression profiles, which may remain even after the initiating signal is removed (FIG. 6) . This may have important therapeutic implications: treating tumour cells with kinase inhibitors may not be sufficient to restore the deregulated gene expression programmes that are found in these cells, and combining kinase inhibitors with epigenetic drugs that can directly attack the epigenetic aberrancies found in cancer cells may lead to superior therapeutic outcomes.
Despite the recent major advances in the field described in this Review, our understanding of how the cancer epigenome is affected by abnormal oncogenic signalling pathways is still at a nascent stage. As the link between signalling networks and epigenetic modifications solidifies, we hope to obtain a better understanding of how changes in the epigenetic landscape establish and maintain the identitiy of the cancer cell. Thus, although some of these changes are transient and can be easily reversed by removing the signal, others are more persistent and may not be reversed after the initial signal is removed. By phosphorylating histone and/or DNA modifiers, or the histones themselves, signalling pathways can leave their 'fingerprints' on chromatin structure, indicating their earlier presence in the cell. Me, methyl; P, phosphate; RTK, receptor tyrosine kinase.
